Miroslav Terinek

Title: Miroslav Terinek: Innovator in Melanocortin-4 Receptor Antagonists

Introduction

Miroslav Terinek is a notable inventor based in Bubendorf, Switzerland. He has made significant contributions to the field of pharmacology, particularly in the development of compounds that target the melanocortin-4 receptor (MC-4R). His work has implications for treating various disorders, including cancer cachexia and anxiety.

Latest Patents

Miroslav Terinek holds a patent for "Substituted imidazopyridine derivatives as melanocortin-4 receptor antagonists." This invention focuses on substituted imidazopyridine derivatives that act as modulators of the MC-4R. The patent highlights the potential of these antagonists in treating conditions such as muscle wasting, anorexia, amyotrophic lateral sclerosis (ALS), anxiety, and depression. He has 1 patent to his name.

Career Highlights

Throughout his career, Miroslav has worked with prominent companies in the pharmaceutical industry. Notably, he has been associated with Santhera Pharmaceuticals AG, where he contributed to innovative research and development efforts. His expertise in pharmacology has positioned him as a valuable asset in the field.

Collaborations

Miroslav Terinek has collaborated with esteemed colleagues, including Günther Metz and Holger Deppe. These partnerships have fostered a collaborative environment that enhances the research and development of new therapeutic agents.

Conclusion

Miroslav Terinek's contributions to the field of pharmacology, particularly through his patent on melanocortin-4 receptor antagonists, demonstrate his commitment to advancing medical science. His work has the potential to impact the treatment of various debilitating conditions, showcasing the importance of innovation in healthcare.